These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29599449)

  • 1. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C; Wezel F; Southgate J; Bolenz C
    Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
    Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
    Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
    Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating Telomerase
    Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
    [No Abstract]   [Full Text] [Related]  

  • 6. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
    Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase activity: a biomarker of cell proliferation, not malignant transformation.
    Belair CD; Yeager TR; Lopez PM; Reznikoff CA
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13677-82. PubMed ID: 9391085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
    Zheng L; Chen H; Zhao J; Roy-Chowdhuri S; Kamat AM; Alhalabi O; Gao J; Siefker-Radtke A; Hansel DE; Czerniak B; Guo CC
    Hum Pathol; 2024 Jun; 148():1-6. PubMed ID: 38679207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
    Zvereva M; Hosen MI; Forey N; Sheikh M; Kannengiesser C; Ba I; Manel A; Vian E; Le Calvez-Kelm F
    Methods Mol Biol; 2023; 2684():213-228. PubMed ID: 37410237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.
    Wan S; Liu X; Hua W; Xi M; Zhou Y; Wan Y
    Bioengineered; 2021 Dec; 12(1):1495-1504. PubMed ID: 33938397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
    Mollica V; Tassinari E; Santoni M; Marchese PV; Giunchi F; Maloberti T; Tateo V; Ricci C; Rosellini M; Marchetti A; Fiorentino M; Biase D; Massari F
    Pathol Res Pract; 2024 Jan; 253():155008. PubMed ID: 38103361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of telomerase in cancer.
    Akincilar SC; Unal B; Tergaonkar V
    Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding TERT Promoter Mutations: A Common Path to Immortality.
    Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
    Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
    Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
    EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleeping beauty: awakening urothelium from its slumber.
    Balsara ZR; Li X
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F732-F743. PubMed ID: 28122714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
    Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly recurrent TERT promoter mutations in human melanoma.
    Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
    Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.
    Shuai H; Duan X; Zhou JJ; Liu Y; Wu T
    BMC Urol; 2023 Nov; 23(1):177. PubMed ID: 37915019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An accurate diagnostic approach for urothelial carcinomas based on novel dual methylated DNA markers in small-volume urine.
    Wu Y; Cai D; Fan J; Meng C; He S; Li Z; Zhang L; Yang K; Wang A; Li X; Du Y; Xiong S; Xia M; Li T; Dong L; Gong Y; Zhou L; Li X
    Chin Med J (Engl); 2024 Jan; 137(2):232-234. PubMed ID: 37455255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.